Skip to main content
Terug
CHGCF logo

Chugai Pharmaceutical Co., Ltd.

Datakwaliteit: 100%
CHGCF
OTC Healthcare Drug Manufacturers - General
€ 53,31
▲ € 1,37 (2,63%)
Marktkapitalisatie: 87,72B
Ook genoteerd als CHGCY OTC
Dagbereik
€ 53,31 € 64,01
52-Weeksbereik
€ 38,76 € 72,30
Volume
216
50D / 200D Gem.
€ 58,19 / € 51,05
Vorige Slotkoers
€ 51,94

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 0,2 0,3
P/B 0,0 2,9
ROE % 22,1 3,7
Net Margin % 34,5 3,8
Rev Growth 5Y % 5,9 10,0
D/E 0,0 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 531,16
€ 488,31 – € 574,26
 1900 B 5
FY2029 € 481,84
€ 442,97 – € 520,94
 1900 B 2
FY2028 € 392,11
€ 360,48 – € 423,93
 1600 B 5

Belangrijkste Punten

Revenue grew 5,93% annually over 5 years — modest growth
ROE of 22,11% indicates high profitability
Net margin of 34,50% shows strong profitability
Debt/Equity of 0,00 — conservative balance sheet
Generating 313,45B in free cash flow
P/E of 0,20 — trading at a low valuation

Groei

Revenue Growth (5Y)
5,93%
Revenue (1Y)7,55%
Earnings (1Y)12,15%
FCF Growth (3Y)-3,37%

Kwaliteit

Return on Equity
22,11%
ROIC21,85%
Net Margin34,50%
Op. Margin46,92%

Veiligheid

Debt / Equity
0,00
Current Ratio4,23
Interest Coverage575,24

Waardering

P/E Ratio
0,20
P/B Ratio0,04
EV/EBITDA-0,57
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 7,55% Revenue Growth (3Y) 6,44%
Earnings Growth (1Y) 12,15% Earnings Growth (3Y) 15,53%
Revenue Growth (5Y) 5,93% Earnings Growth (5Y) 9,42%
Profitability
Revenue (TTM) 1,26T Net Income (TTM) 434,39B
ROE 22,11% ROA 17,58%
Gross Margin 71,09% Operating Margin 46,92%
Net Margin 34,50% Free Cash Flow (TTM) 313,45B
ROIC 21,85% FCF Growth (3Y) -3,37%
Safety
Debt / Equity 0,00 Current Ratio 4,23
Interest Coverage 575,24 Dividend Yield 0,02%
Valuation
P/E Ratio 0,20 P/B Ratio 0,04
P/S Ratio 0,07 PEG Ratio 2,68
EV/EBITDA -0,57 Dividend Yield 0,02%
Market Cap 87,72B Enterprise Value -339,25B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,26T 1,17T 1,11T 1,26T 999,76B
Net Income 434,39B 387,32B 325,47B 374,43B 303,00B
EPS (Diluted) 263,95 235,36 197,80 227,57 184,17
Gross Profit 895,03B 831,20B 698,06B 783,70B 661,61B
Operating Income 590,71B 542,00B 439,17B 533,31B 421,90B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,47T 2,21T 1,93T 1,87T 1,54T
Total Liabilities 443,25B 306,87B 306,97B 445,37B 350,68B
Shareholders' Equity 2,03T 1,90T 1,63T 1,42T 1,19T
Total Debt 0,0 10,90B 13,46B 14,11B 16,04B
Cash & Equivalents 426,97B 540,20B 458,67B 222,17B 267,75B
Current Assets 1,74T 1,61T 1,37T 1,34T 1,06T
Current Liabilities 411,44B 290,36B 288,22B 423,73B 327,42B

Strategiescores

This stock passed the criteria for 5 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Capital Light Compounder
#45 of 218
53
Custom Deep Value Investing (Seth Klarman)
#518 of 827
36
Custom Contrarian Investing (David Dreman)
#539 of 670
11
Value Defensive Investing (Benjamin Graham)
#639 of 709
4
Value Value Investing (Warren Buffett)
#193 of 203
20

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Capital Light Compounder
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026
Ingestapt Value Investing (Warren Buffett)
Mar 24, 2026